Ambu's Q3 ended better than expected

After a downgrade earlier in the year, pessimism had grown regarding Ambu's third quarter, though it turned out to go slightly above expectations. The launch of one of the firm's new products is postponed, however.

Photo: PR / Ambu

The third-quarter financials of Danish medical technology firm Ambu ended up slightly better than expected earlier this year after the company presented preliminary figures in connection with a downgrade.

Ambu now reports that its revenue has come to just above the DKK 971m (USD 153.6m) announced in July, and the DKK 62m bottom line is well above the DKK 49m forecast by analysts.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs